Literature DB >> 20559907

Advances in gene-based therapy for heart failure.

Hung Q Ly1, Yoshiaki Kawase, Roger J Hajjar.   

Abstract

Heart failure is a major cause of morbidity and mortality in western countries. While progress in current treatment modalities is making steady and incremental gains to reduce this disease burden, there remains a need to explore novel therapeutic strategies. Clinicians and researchers alike have thus looked towards novel adjunctive therapeutic strategies, including gene-based therapy for congestive heart failure (CHF). Advances in the understanding of the molecular basis of CHF, combined to the evolution of increasingly efficient gene transfer technology, have placed congestive heart failure within reach of gene-based therapy. This review will discuss issues related to gene vector systems, gene delivery strategies, and gene targets for intervention in the setting of CHF.

Entities:  

Mesh:

Year:  2008        PMID: 20559907     DOI: 10.1007/s12265-008-9022-4

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  107 in total

Review 1.  In vivo gene transfer: a biological tool.

Authors:  E G Nabel; R Simari; Z Yang; H San; G J Nabel
Journal:  Ann N Y Acad Sci       Date:  1997-04-15       Impact factor: 5.691

Review 2.  Ca(2+)-handling proteins and heart failure: novel molecular targets?

Authors:  J Prestle; F R Quinn; G L Smith
Journal:  Curr Med Chem       Date:  2003-06       Impact factor: 4.530

3.  The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells.

Authors:  A Sirven; F Pflumio; V Zennou; M Titeux; W Vainchenker; L Coulombel; A Dubart-Kupperschmitt; P Charneau
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

4.  Targeting phospholamban by gene transfer in human heart failure.

Authors:  Federica del Monte; Sian E Harding; G William Dec; Judith K Gwathmey; Roger J Hajjar
Journal:  Circulation       Date:  2002-02-26       Impact factor: 29.690

Review 5.  Assessment of risks associated with cardiovascular gene therapy in human subjects.

Authors:  J M Isner; P R Vale; J F Symes; D W Losordo
Journal:  Circ Res       Date:  2001-08-31       Impact factor: 17.367

6.  Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia.

Authors:  P R Vale; D W Losordo; C E Milliken; M C McDonald; L M Gravelin; C M Curry; D D Esakof; M Maysky; J F Symes; J M Isner
Journal:  Circulation       Date:  2001-05-01       Impact factor: 29.690

7.  Efficient gene transfer into myocardium by direct injection of adenovirus vectors.

Authors:  R J Guzman; P Lemarchand; R G Crystal; S E Epstein; T Finkel
Journal:  Circ Res       Date:  1993-12       Impact factor: 17.367

8.  Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium.

Authors:  M A Movsesian; M Karimi; K Green; L R Jones
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

Review 9.  Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation.

Authors:  Larissa Lipskaia; Anne-Marie Lompré
Journal:  Biol Cell       Date:  2004-02       Impact factor: 4.458

10.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.

Authors:  Yoshitaka Iwanaga; Masahiko Hoshijima; Yusu Gu; Mitsuo Iwatate; Thomas Dieterle; Yasuhiro Ikeda; Moto-o Date; Jacqueline Chrast; Masunori Matsuzaki; Kirk L Peterson; Kenneth R Chien; John Ross
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

View more
  2 in total

1.  AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.

Authors:  Brian Bostick; Jin-Hong Shin; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

2.  An attenuated coxsackievirus b3 vector: a potential tool for viral tracking study and gene delivery.

Authors:  Jun Zeng; Xiao xuan Chen; Jian ping Dai; Xiang feng Zhao; Gang Xin; Yun Su; Ge fei Wang; Rui Li; Yin xia Yan; Jing hua Su; Yu xue Deng; Kang sheng Li
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.